湿疹面积和严重度指数(EASI)使用20年后的进展与挑战更新
该综述回顾了EASI在特应性皮炎临床体征测量中的验证情况,依据标准评估标准发现其性能满足COSMIN对临床体征报告工具的要求,具有临床可解释性,适用于所有严重度。部分验证缺口仍存,尤其在深色皮肤人群中的表现数据有限,技术适配初显潜力,建议所有干预性特应性皮炎试验使用EASI。
要点
- EASI在成人和儿童特应性皮炎中广泛验证,被HOME推荐为核心结局指标。
- EASI满足COSMIN对临床体征报告工具的性能要求,具有临床可解释性。
- 深色皮肤人群的验证数据有限,技术适配(远程/自动化评估)初显前景。
核心结论
- EASI在测量特应性皮炎临床体征方面表现出足够的性能,适用于所有严重度,无强证据限制其在试验或临床实践中的使用。
研究设计与样本
- 本文为综述,使用标准评估标准回顾EASI的验证情况,并探讨其普遍适用性的争议与挑战及未来电子化适配。
主要发现
- EASI在成人和儿科人群中广泛验证,被HOME倡议推荐为临床试验中评估临床体征的核心结局指标。
- EASI满足COSMIN推荐的临床体征报告工具的性能要求,具有临床可解释性,适用于所有特应性皮炎严重度。
- 在多样人群(尤其是深色皮肤)中的性能报告数据有限但前景可观;技术适配的初步验证结果积极。
- 关于研究者培训效果的问题仍存,但无强证据限制EASI在试验或临床实践中的使用。
关键数值与推荐
- EASI被推荐用于所有干预性特应性皮炎试验,并应与其他推荐的临床实践严重度工具一起考虑。
- EASI被HOME倡议推荐为临床试验中评估临床体征的核心结局指标,近期也被推荐作为临床实践中测量体征的选项。
临床怎么用
- 在临床实践中可将EASI作为测量特应性皮炎体征的选项之一,并与其他推荐的严重度工具联合使用。
- 在干预性特应性皮炎试验中应使用EASI作为评估临床体征的核心结局指标。
局限性
- 部分验证缺口仍存,尤其在多样人群( emphasis on deeply pigmented skin)中的性能报告有限。
- 关于研究者培训对EASI测量效果的影响尚存疑问。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Eczema Area and Severity Index is an investigator-assessed instrument reporting clinical signs of atopic dermatitis. The instrument is extensively validated in both adult and paediatric populations and recommended as a core outcome measure to assess clinical signs by the Harmonising Outcome Measures for Eczema initiative in clinical trials and was recently recommended as an option to measure signs in clinical practice. Here, we review the validation of the instrument using standard assessment criteria, explore controversies and challenges to its universal applicability and highlight future electronic adaptations. We find that the instrument demonstrates adequate performance in the measurement properties recommended by the COnsensus-based Standards for the selection of health Measurement INstruments initiative for instruments reporting clinical signs, is clinically interpretable, and is suitable for all atopic dermatitis severities. Some validation gaps remain. Information reporting on its performance in diverse populations, with emphasis on deeply pigmented skin, is promising though limited. Technological adaptations are demonstrating promising initial validation results and may facilitate remote and/or automated assessments assisting clinical care and decentralized clinical trials in the future. We find no strong evidence limiting its use in trials or clinical practice although questions pertaining to the effect of investigator training remain. We recommend that the Eczema Area and Severity Index be used in all interventional atopic dermatitis trials and be considered alongside other recommended clinical practice severity instruments.
引用
- Jacobson ME, Morimoto RY, Leshem YA, et al. The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use. J Eur Acad Dermatol Venereol. 2024. PMID: 39157949. doi:10.1111/jdv.20248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。